Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$42.45 USD
+0.61 (1.46%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $42.54 +0.09 (0.21%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Ionis Pharmaceuticals (IONS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$60.47 | $85.00 | $45.00 | 42.45% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Ionis Pharmaceuticals comes to $60.47. The forecasts range from a low of $45.00 to a high of $85.00. The average price target represents an increase of 44.53% from the last closing price of $41.84.
Analyst Price Targets (17)
Broker Rating
Ionis Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.84 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 1.89 a month ago based on 18 recommendations.
Of the 19 recommendations deriving the current ABR, 11 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 57.89% and 10.53% of all recommendations. A month ago, Strong Buy made up 55.56%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 10 | 10 | 10 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 5 | 5 | 5 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.84 | 1.84 | 1.89 | 1.89 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/9/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
4/9/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
4/1/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
1/18/2024 | Piper Sandler | Allison M Bratzel | Strong Buy | Strong Buy |
1/11/2024 | SVB Securities | Mani Foroohar | Hold | Hold |
11/14/2023 | Guggenheim Securities | Debjit Chattopadhyay | Not Available | Strong Buy |
9/29/2023 | Raymond James | Gary Nachman | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.84 |
ABR (Last week) | 1.84 |
# of Recs in ABR | 19 |
Average Target Price | $60.47 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 252 |
Current Quarter EPS Est: | -1.07 |